- Home
- PTEN vs VRNA Comparison
PTEN vs VRNA Comparison
Compare PTEN & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTEN
- VRNA
- Stock Information
- Founded
- PTEN 1978
- VRNA 2005
- Country
- PTEN United States
- VRNA United Kingdom
- Employees
- PTEN N/A
- VRNA N/A
- Industry
- PTEN Oil & Gas Production
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- PTEN Energy
- VRNA Health Care
- Exchange
- PTEN Nasdaq
- VRNA Nasdaq
- Market Cap
- PTEN 3.0B
- VRNA 3.4B
- IPO Year
- PTEN 1993
- VRNA 2017
- Fundamental
- Price
- PTEN $9.25
- VRNA $53.30
- Analyst Decision
- PTEN Buy
- VRNA Strong Buy
- Analyst Count
- PTEN 13
- VRNA 7
- Target Price
- PTEN $11.96
- VRNA $53.14
- AVG Volume (30 Days)
- PTEN 8.9M
- VRNA 1.4M
- Earning Date
- PTEN 02-05-2025
- VRNA 02-27-2025
- Dividend Yield
- PTEN 3.47%
- VRNA N/A
- EPS Growth
- PTEN N/A
- VRNA N/A
- EPS
- PTEN N/A
- VRNA N/A
- Revenue
- PTEN $5,800,093,000.00
- VRNA $5,624,000.00
- Revenue This Year
- PTEN $34.04
- VRNA N/A
- Revenue Next Year
- PTEN N/A
- VRNA $568.20
- P/E Ratio
- PTEN N/A
- VRNA N/A
- Revenue Growth
- PTEN 73.11
- VRNA 1127.95
- 52 Week Low
- PTEN $7.15
- VRNA $11.39
- 52 Week High
- PTEN $12.65
- VRNA $55.42
- Technical
- Relative Strength Index (RSI)
- PTEN 68.43
- VRNA 64.77
- Support Level
- PTEN $8.42
- VRNA $43.44
- Resistance Level
- PTEN $9.57
- VRNA $55.42
- Average True Range (ATR)
- PTEN 0.29
- VRNA 3.35
- MACD
- PTEN 0.11
- VRNA 0.40
- Stochastic Oscillator
- PTEN 81.71
- VRNA 73.19
About PTEN Patterson-UTI Energy Inc.
Patterson-UTI Energy is one of the largest land rig drilling contractors in the United States. Its 2023 merger with NexTier greatly expanded its pressure pumping operations, as well, and the firm now controls nearly 20% of the North American market for drilling and completions services. It also provides directional drilling services and tool rental services in most US onshore oil and gas basins.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.